: Edwards Lifesciences to spin off critical-care unit, sets $1B stock buyback

Katie Szyman will be chief executive of the independent company, which is expected to generate $905 million in sales in 2023.

Previous post Retail lobby group’s retraction of key crime claim shows how hard it is to track theft
Next post Key Words: Elizabeth Warren says Elon Musk’s Twitter buy shows need for wealth tax in U.S.